Dargie H J, Boddy K, Kennedy A C, King P C, Read P R, Ward D M
Br Med J. 1974 Nov 9;4(5940):316-9. doi: 10.1136/bmj.4.5940.316.
Measurements of total body potassium (T.B.K.) were made by whole-body counting in four groups of patients receiving oral frusemide for one year. Patients in group 1 had essential hypertension and normal renal function and received 40 mg frusemide daily without potassium supplements. Patients in group 2 were similar but received oral potassium supplements for the first four months of treatment. Patients in group 3 had hypertension associated with renal disease and received 120 mg frusemide daily without potassium supplements. Patients in group 4 also had hypertension and renal impairment and in addition to 120 mg frusemide daily they received oral potassium supplements for four months. No evidence of depletion of T.B.K. was found in any of the groups after continuous treatment with frusemide for one year. It is questioned whether potassium supplementation in long term diuretic therapy with frusemide is necessary unless there is evidence of pre-existing potassium depletion or of some other factor such as cardiac failure, cirrhosis of the liver, or the nephrotic syndrome.
对四组接受口服速尿治疗一年的患者进行了全身钾(T.B.K.)测量。第1组患者患有原发性高血压且肾功能正常,每日服用40毫克速尿且不补充钾。第2组患者情况类似,但在治疗的前四个月补充口服钾。第3组患者患有与肾脏疾病相关的高血压,每日服用120毫克速尿且不补充钾。第4组患者也患有高血压和肾功能损害,除每日服用120毫克速尿外,还补充口服钾四个月。在使用速尿连续治疗一年后,任何一组均未发现全身钾耗竭的证据。有人质疑,在使用速尿进行长期利尿治疗时,除非有先前存在钾耗竭的证据或存在诸如心力衰竭、肝硬化或肾病综合征等其他因素,否则是否有必要补充钾。